0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover102.42%IV-28.55%PremiumDec 20, 2024Expiry Date7.99Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9168Delta0.0203Gamma3.39Leverage Ratio-0.0247Theta0.0120Rho3.11Eff Leverage0.0112Vega
Spyre Therapeutics Stock Discussion
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Spyre Therapeutics (NASDAQ: SYRE) has priced its public offering of 7,275,000 common stock shares at $27.50 per share, expecting to raise $200.0 million in gross proceeds. The clinical-stage biotech company, focused on IBD treatments, has granted underwriters a 30-day option to purchase up to additional 1,091,250 shares. The offering, managed by Jefferies, Goldman Sachs, Evercor...
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$